refractory uveitis of Behcet'
Conditions
Interventions
Patients with Behcet'
s disease who has received Infliximab intravenous infusion treatment at 8 week intervals over a long period (over 4 years) and calm eye inflammation, shall be discontinued from infliximab and be chang
Sponsors
Yokohama City University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Infliximab intravenous treatment is performed for 8 weeks at long intervals (over 4 years) 2. Eye symptoms and extraocular symptoms are calm 3. Over 20 years old
Exclusion criteria
Exclusion criteria: 1. Patients with kidney dysfunction 2. Patients with liver dysfunction 3. Patients with pancreatic dysfunction 4. Hypertension patients 5. Patients with infection 6. Patients with malignant tumors (such as malignant lymphoma) or a previous medical history 7. Patients during ultraviolet radiation therapy including PUVA therapy 8. Elderly (65 years and over) 9. Hepatitis B virus carrier, patient with hepatitis C virus carrier 10. Patients who are using contraindicated drugs in combination with cyclosporine,Living vaccine (dry live attenuated measles vaccine, dry live attenuated feline vaccine, oral raw polio vaccine, dry raw BCG, etc.), tacrolimus excluding external medicine (prograf), pitavastatin ), Rosuvastatin (crestor), bosentan (trakuria), aliskiren (radiolith), asnaprevir (sunbella), baniprevir (bani hep) 11. Other patients judged inappropriate by the research doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcomes is the proportion of cases in which Infliximab is reintroduced in one year from the start of Infliximab withdrawal. Because the number of cases is small, if the proportion of re-introduction of Infliximab is 20% or less, it is acceptable. | — |
Countries
Japan
Contacts
Public ContactYasutsugu Ida
Yokohama City University School of Medicine Department of Ophthalmology
Outcome results
None listed